Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 2/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | PREP | P48147 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 3/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8342335 | 0.81 | XIAP (0.49) | CASP1PREPALDH1A1GAANAAA | |
| SCHEMBL8344263 | 0.81 | MMP2 (0.49) | CASP1MMP2PREPALDH1A1GAA | |
| SCHEMBL28777589 | 0.81 | CASP1 (0.48) | CASP1PREPALDH1A1GAAACE | |
| SCHEMBL8339321 | 0.80 | ALDH1A1 (0.46) | CASP1PREPALDH1A1GAAMEN1 | |
| SCHEMBL5355014 | 0.77 | CASP1 (0.47) | CASP1MMP2PREPALDH1A1GAA | |
| SCHEMBL6697127 | 0.77 | MMP2 (0.46) | CASP1MMP2PREPALDH1A1GAA | |
| SCHEMBL21752950 | 0.77 | CASP1 (0.48) | CASP1PREPALDH1A1GAAMEN1 | |
| SCHEMBL23882012 | 0.76 | CASP1 (0.49) | CASP1PREPALDH1A1GAAMEN1 | |
| SCHEMBL425375 | 0.76 | ALDH1A1 (0.58) | PREPALDH1A1GAANAAATSHR | |
| SCHEMBL6216047 | 0.75 | SMN1; SMN2 (0.59) | PREPALDH1A1GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210309649-A1 | SUBSTITUTED GLUTARIMIDE DERIVATIVES | BASF SE (DE) | 2021-10-07 | — | — | US | disclosed |
| EP-3841099-A1 | SUBSTITUTED GLUTARIMIDE DERIVATIVES | BASF SE (DE) | 2021-06-30 | — | — | EP | disclosed |
| WO-2020038821-A1 | SUBSTITUTED GLUTARIMIDE DERIVATIVES | BASF SE (DE) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309649-A1 | SUBSTITUTED GLUTARIMIDE DERIVATIVES | GLRX3, GCDH, GCLC | CASP1 976/4885MMP2 2152/4885PREP 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.